Opinion|Videos|September 3, 2024

Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial

Medical experts offer insights on the COMMANDS trial findings.

Video content above is prompted by the following:

  • Discuss the expanded indication of luspatercept in lower-risk myelodysplastic syndromes (based on the COMMANDS trial findings) and its implications for clinical practice.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo